Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04579588 · ClinicalTrials.gov registry record
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
A clinical trial of Corona Virus Infection and Immunity, sponsored by Stanford University.
- Recruiting
- Registry status
- 230
- Enrollment target
- 1
- Study location
NCT04579588: Recruiting study of Corona Virus Infection and Immunity, sponsored by Stanford University.
NCT04579588 is a study of Corona Virus Infection and Immunity that is actively recruiting participants, run by Stanford University. The registered enrollment target is 230 participants, below the 578-participant average among 28 other Corona Virus Infection trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04579588, a study of Corona Virus Infection and Immunity, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 230 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.
Conditions Studied
Interventions
- BIOLOGICAL Flu shot
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2028-04 |
What NCT04579588 shows while recruiting
NCT04579588 is an observational study that tracks outcomes without assigning an intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 578-participant average among 28 other Corona Virus Infection trials with a reported enrollment target (60% lower).
The record links to 3 conditions, with Corona Virus Infection appearing as the primary indexed condition, and to 1 intervention - of which Flu shot is the first listed.
NCT04579588 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04579588 about?
NCT04579588 is a clinical study titled "Understanding Immunity to the Flu Vaccine in COVID-19 Patients". The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COV...
What is the current status of trial NCT04579588?
This trial is currently recruiting. The enrollment target is 230 participants. The study started on 2020-10-29. Estimated completion is 2028-04.
What conditions does trial NCT04579588 study?
This clinical trial studies the following conditions: Corona Virus Infection, Immunity, Flu Vaccine.
What interventions are being tested in trial NCT04579588?
The interventions under investigation include: Flu shot (BIOLOGICAL).
Who is sponsoring clinical trial NCT04579588?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04579588 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corona Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04579588's enrollment target sits among peer trials
230 13th of 28 higher than 16 of 28 other Corona Virus Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Corona Virus Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children
RECRUITING
-
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
RECRUITING
-
A Study to Explore the Role of Gut Flora in COVID-19 Infection
RECRUITING
-
KIDney Injury in Times of COVID-19 (KIDCOV)
RECRUITING
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI